Lenalidomide Teva

Lenalidomide, the active ingredient in Lenalidomide Teva, is an immunomodulatory drug (IMiD) presented as an oral tablet for oral use. It is indicated for the treatment of multiple myeloma and for myelodysplastic syndromes that carry the del(5q) chromosome abnormality in adult patients.

GNH USA supplies Lenalidomide Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand.

Lenalidomide is used in hematologic malignancies and related disorders, targeting abnormal plasma cells and dysplastic bone‑marrow clones. - Multiple Myeloma: improves progression‑free and overall survival in patients with relapsed or refractory disease. - Myelodysplastic Syndromes with del(5q): reduces transfusion dependence and can induce cytogenetic remission. - Maintenance Therapy after Autologous Stem Cell Transplant: prolongs remission duration in eligible multiple myeloma patients.

Lenalidomide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Fatigue: persistent tiredness affecting daily activities. - Neutropenia: reduced neutrophil count increasing infection risk. - Thrombocytopenia: lowered platelet levels that may cause easy bruising. - Diarrhea: loose stools that may be mild to moderate. - Rash: skin eruptions that are usually mild. - Constipation: difficulty passing stools.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins or lungs. - Severe neutropenia or febrile neutropenia: high infection risk requiring hospitalization. - Severe thrombocytopenia: significant bleeding risk. - Secondary primary malignancies: emergence of new cancers. - Stevens‑Johnson syndrome or toxic epidermal necrolysis: severe skin reactions. - Hepatic failure: marked liver enzyme elevation and dysfunction.

Before initiating lenalidomide therapy, several safety considerations should be addressed. - Blood Count Monitoring: perform complete blood counts regularly to detect cytopenias. - Thromboembolic Risk Assessment: evaluate for clotting risk and consider prophylactic anticoagulation when indicated. - Pregnancy Prevention: enforce strict contraception for both male and female patients of reproductive potential. - Renal Function Evaluation: adjust therapy based on creatinine clearance in patients with impaired kidney function. - Infection Surveillance: monitor for signs of infection and manage promptly. - Store at room temperature: keep tablets in the original container, protect from moisture and light.

Lenalidomide can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase lenalidomide exposure. - Anticoagulants (warfarin, direct oral anticoagulants): heightened risk of bleeding. - Live vaccines: risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce drug levels. - NSAIDs or aspirin: may exacerbate thrombocytopenia. - Digoxin: potential for altered serum concentrations.